The sale of assets from Novartis' radiopharma unit could potentially bring in significant revenue for the company, which could positively impact its financials and stock price. However, it could also mean a reduction in future revenue streams from these assets, which could negatively impact the company's long-term financial outlook. The impact on the stock price will depend on the details of the sale, including the price and the buyer, which are not yet known.